Share this article
Share this article
SAN DIEGO, Feb. 16, 2021 /PRNewswire/ Prometheus Biosciences, Inc. ( Prometheus ), a biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of inflammatory bowel disease (IBD), today announced the appointments of Judith L. Swain, MD and Helen C. Adams to its board of directors. Ms. Adams will assume the position of Chair of the Audit Committee. We re thrilled to have Judith and Helen join our Board of Directors, who bring significant clinical medicine and financial expertise that will be important as we advance our pipeline to people living with IBD, said Mark McKenna, President and CEO of Prometheus. Judith is a distinguished physician scientist and veteran scientific advisory board member with an international perspective on drug development. Helen is an outstanding financial professional and exper